Dolutegravir dual therapy works well for both first line and maintenance treatment
First trial results of new immune-modulating drugs presented in Mexico City
Islatravir plus doravirine may offer new dual therapy option
PrEP implant could last well over a year
People with HIV express high satisfaction with monthly injectable regimen
US regulators approve new two-drug combination pill for HIV
HIV capsid inhibitor may offer long-term viral suppression
Long-acting injectable treatment maintains viral suppression
Integrase inhibitor treatment leads to greater weight gain
